Could a vaccine combo free people with HIV from daily pills?

NCT ID NCT06071767

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a special T-cell vaccine, combined with an immune-boosting drug (vesatolimod) and two powerful antibodies, can help people with HIV control the virus without needing daily antiretroviral therapy. The trial involves 36 adults who started HIV treatment soon after infection and have been on stable therapy for at least a year. Participants will receive the vaccine regimen or a placebo, then temporarily stop their regular HIV meds to see if the new approach keeps the virus in check.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

T-cell vaccine (ChAdOx1-MVA/HIVconsvX), vesatolimod, and broadly neutralizing antibodies (GS-5423, GS-2872)

What this could lead to

If successful, this could point toward a way for people with HIV to stop daily antiretroviral therapy while keeping the virus under control.

What could go wrong

This is an early-phase trial with only 36 participants, so results may not apply broadly. The combination regimen is complex and may cause side effects or fail to control the virus.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chapel Hill CRS

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Columbia Physicians & Surgeons CRS

    RECRUITING

    New York, New York, 10032, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Houston AIDS Research Team CRS

    RECRUITING

    Houston, Texas, 77004, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS

    NOT_YET_RECRUITING

    Rio de Janeiro, Brazil

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 91350-180, Brazil

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Massachusetts General Hospital CRS (MGH CRS)

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Northwestern University CRS

    RECRUITING

    Chicago, Illinois, 60611, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Ohio State University CRS

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Penn Therapeutics CRS

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Ponce de Leon Center CRS

    RECRUITING

    Atlanta, Georgia, 30308, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of California, San Diego AntiViral Research Center CRS

    RECRUITING

    San Diego, California, 92103, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Washington University Therapeutics CRS

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••